美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果刍议

Clinical Effect of Metoprolol Combined with Trimetazidine in the Treatment of Coronary Heart Disease with Heart Failure

目的探究美托洛尔联合曲美他嗪在冠心病心力衰竭疾病中的临床治疗效果。方法方便选取于2016年1月—2018年2月份该院收治的120例慢性肺源性心脏病心力衰竭患者,随机分成两组,即对照组和观察组,每组60例。给予对照组患者美托洛尔治疗方法,给予观察组患者美托洛尔联合曲美他嗪治疗方法。观察治疗前后两组患者的DBP、SBP、LVEDD、LVESD、LVEF、HR、心率、收缩压指标及疾病临床治疗效果。结果治疗后,观察组患者的DBP、SBP、LVEDD、LVESD、LVEF、HR指标分别为(77.65±6.52)mmHg、(119.52±10.53)mmHg、(53.74±4.13)mm、(36.24±2.63)mm、(50.35±3.52)%、(74.43±6.72)次/min。对照组患者的DBP、SBP、LVEDD、LVESD、LVEF、HR指标分别为(86.35±7.46)mmHg、(134.25±15.43)mmHg、(58.53±3.85)mm、(40.52±2.76)mm、(44.83±3.32)%、(90.32±7.25)次/min。观察组患者的各项指标均优于对照组,差异有统计学意义(P<0.05)。治疗后,观察组患者心率为(87.5±6.8)次/min,收缩压为(132.3±10.5)mmHg。对照组患者心率为(69.2±6.5)次/min,收缩压为(112.3±6.8)mmHg。观察组患者的心率及收缩压均高于对照组,差异有统计学意义(P<0.05)。观察组患者总有效例数为58例,有效率为96.67%。对照组患者总有效例数为48例,有效率为80.00%,临床治疗有效率高于对照组,差异有统计学意义(χ2=8.086 25,P<0.05)。结论在冠心病心力衰竭疾病治疗中融入美托洛尔联合曲美他嗪治疗方法,有助于优化患者的各项临床指标,提升患者的心率及收缩压,促进患者疾病治疗效果的提高。

Objective To investigate the clinical therapeutic effect of metoprolol combined with trimetazidine in patients with coronary heart disease and heart failure.Methods A total of 120 patients with chronic pulmonary heart disease and heart failure admitted to our hospital from January 2016 to February 2018 were convenient selected and randomly divided into two groups,the control group and the observation group,with 60 cases in each group.Metoprolol treatment was given to the control group,and metoprolol combined with trimetazidine was given to the observation group.The DBP,SBP,LVEDD,LVESD,LVEF,HR,heart rate,systolic blood pressure and clinical treatment effects of the two groups were observed before and after treatment.Results After treatment,the DBP,SBP,LVEDD,LVESD,LVEF,and HR indexes of the observation group were(77.65±6.52)mmHg,(119.52±10.53)mmHg,(53.74±4.13)mm,(36.24±2.63)mm,(50.35±3.52)%,(74.43±6.72)times/min.The DBP,SBP,LVEDD,LVESD,LVEF,and HR indexes of the control group were(86.35±7.46)mmHg,(134.25±15.43)mmHg,(58.53±3.85)mm,(40.52±2.76)mm,(44.83±3.32)%,(90.32±7.25)times/min.The indexes of the observation group were better than the control group,and the difference was statistically significant(P<0.05).After treatment,the heart rate of the observation group was(87.5±6.8)times/min,and the systolic blood pressure was(132.3±10.5)mmHg.The heart rate of the control group was(69.2±6.5)times/min,and the systolic blood pressure was(112.3±6.8)mmHg.The heart rate and systolic blood pressure of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).The total number of effective patients in the observation group was 58 and the effective rate was 96.67%.The total effective number of patients in the control group was 48,the effective rate was 80.00%,and the clinical treatment efficiency was higher than that of the control group.The difference was statistically significant(χ^2=8.086 25,P<0.05).Conclusion The combination of metoprolol and trimetazidine in the treatment of coronary heart disease with heart disease can help to optimize the clinical indicators of patients,improve the heart rate and systolic blood pressure of patients,and promote the improvement of patients'disease treatment.